Reviva Pharmaceuticals Statistics
Share Statistics
Reviva Pharmaceuticals has 33.44M shares outstanding. The number of shares has increased by 18.54% in one year.
| Shares Outstanding | 33.44M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 10.99% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 28.50M |
| Failed to Deliver (FTD) Shares | 3.84K |
| FTD / Avg. Volume | 0.34% |
Short Selling Information
The latest short interest is 5.30M, so 15.84% of the outstanding shares have been sold short.
| Short Interest | 5.30M |
| Short % of Shares Out | 15.84% |
| Short % of Float | 18.59% |
| Short Ratio (days to cover) | 19.04 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -1.63.
| PE Ratio | 0 |
| Forward PE | -1.63 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 21.43 |
| P/FCF Ratio | -4.33 |
| PEG Ratio | n/a |
Enterprise Valuation
Reviva Pharmaceuticals Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 0.
| Current Ratio | 1.38 |
| Quick Ratio | 1.38 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -6865323.79% and return on capital (ROIC) is 297648609312.16%.
| Return on Equity (ROE) | -6865323.79% |
| Return on Assets (ROA) | -1656548.28% |
| Return on Capital (ROIC) | 297648609312.16% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2,617.40B |
| Employee Count | 15 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -16.95B |
| Effective Tax Rate | 431.89 |
Stock Price Statistics
The stock price has increased by -30.69% in the last 52 weeks. The beta is -0.06, so Reviva Pharmaceuticals 's price volatility has been lower than the market average.
| Beta | -0.06 |
| 52-Week Price Change | -30.69% |
| 50-Day Moving Average | 1.3 |
| 200-Day Moving Average | 1.76 |
| Relative Strength Index (RSI) | 84.68 |
| Average Volume (20 Days) | 1.12M |
Income Statement
In the last 12 months, Reviva Pharmaceuticals had revenue of $0 and earned -$39,260.80B in profits. Earnings per share was $-1.65.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -39,503.60B |
| Net Income | -39,260.80B |
| EBITDA | -39,503.60B |
| EBIT | - |
| Earnings Per Share (EPS) | -1.65 |
Balance Sheet
The company has $23.37M in cash and $0 in debt, giving a net cash position of $23.37M.
| Cash & Cash Equivalents | 23.37M |
| Total Debt | 0 |
| Net Cash | 23.37M |
| Retained Earnings | -134.35M |
| Total Assets | 7.63M |
| Working Capital | -10.72M |
Cash Flow
In the last 12 months, operating cash flow was -$28.32M and capital expenditures $0, giving a free cash flow of -$28.32M.
| Operating Cash Flow | -28.32M |
| Capital Expenditures | 0 |
| Free Cash Flow | -28.32M |
| FCF Per Share | -1.19 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
RVPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -62.98% |
| FCF Yield | -32.27% |
Analyst Forecast
The average price target for RVPH is $15, which is 472.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $15 |
| Price Target Difference | 472.5% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -38.79 |
| Piotroski F-Score | 1 |